Venetoclax penetrates in cerebrospinal fluid and may be
effective in chronic lymphocytic leukemia with central nervous
system involvement

J 2019

Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement

REDA, Gianluigi, Ramona CASSIN, Gabriela DOVRTĚLOVÁ, Cristina MATTEO, Juri GIANNOTTA et. al.

Basic information

Original name

Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement

Authors

REDA, Gianluigi (380 Italy), Ramona CASSIN (380 Italy), Gabriela DOVRTĚLOVÁ (203 Czech Republic, guarantor, belonging to the institution), Cristina MATTEO, Juri GIANNOTTA (380 Italy), Maurizio D'INCALCI (380 Italy), Agostino CORTELEZZI (380 Italy) and Massimo ZUCCHETTI (380 Italy)

Edition

Haematologica, Itálie, Ferrata Storti Foundation, 2019, 0390-6078

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

Italy

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 7.116

RIV identification code

RIV/00216224:14110/19:00109502

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3324/haematol.2018.213157

UT WoS

000466305600012

Keywords in English

CNS involvement; Chronic Lymphocytic Leukemia; venetoclax

Abstract

V originále

Venetoclax, a selective inhibitor of BCL2, has shown promising efficacy in chronic lymphocytic leukemia (CLL) both as single agent or in combination therapy. Central nervous system involvement (CNSi) is a rare complication of CLL and is reported in approximately 0.4% of patients. Therapeutic guidelines have not yet been established and prognosis for these patients is poor. Few cases of CLL with CNSi have been reported until now, and ibrutinib was successfully used due to its ability to penetrate the blood-brain barrier.

Links

CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU
(CEP code: EF16_013/0001826)

Name: CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií

Investor: Ministry of Education, Youth and Sports of the CR, Priority axis 1: Strengthening capacities for high-quality research

LM2015090, research and development project

Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

REDA, Gianluigi, Ramona CASSIN, Gabriela DOVRTĚLOVÁ, Cristina MATTEO, Juri GIANNOTTA, Maurizio D'INCALCI, Agostino CORTELEZZI and Massimo ZUCCHETTI. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. Haematologica. Itálie: Ferrata Storti Foundation, 2019, vol. 104, No 5, p. "E222-E223", 2 pp. ISSN 0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2018.213157.

@article{1524093,
   author = {Reda, Gianluigi and Cassin, Ramona and Dovrtělová, Gabriela and Matteo, Cristina and Giannotta, Juri and D'Incalci, Maurizio and Cortelezzi, Agostino and Zucchetti, Massimo},
   article_location = {Itálie},
   article_number = {5},
   doi = {http://dx.doi.org/10.3324/haematol.2018.213157},
   keywords = {CNS involvement; Chronic Lymphocytic Leukemia; venetoclax},
   language = {eng},
   issn = {0390-6078},
   journal = {Haematologica},
   title = {Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement},
   url = {http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract},
   volume = {104},
   year = {2019}
}

TY  - JOUR
ID  - 1524093
AU  - Reda, Gianluigi - Cassin, Ramona - Dovrtělová, Gabriela - Matteo, Cristina - Giannotta, Juri - D'Incalci, Maurizio - Cortelezzi, Agostino - Zucchetti, Massimo
PY  - 2019
TI  - Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement
JF  - Haematologica
VL  - 104
IS  - 5
SP  - "E222-E223"
EP  - "E222-E223"
PB  - Ferrata Storti Foundation
SN  - 03906078
KW  - CNS involvement
KW  - Chronic Lymphocytic Leukemia
KW  - venetoclax
UR  - http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract
L2  - http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract
N2  - Venetoclax, a selective inhibitor of BCL2, has shown promising efficacy in chronic lymphocytic leukemia (CLL) both as single agent or in combination therapy. Central nervous system involvement (CNSi) is a rare complication of CLL and is reported in approximately 0.4% of patients. Therapeutic guidelines have not yet been established and prognosis for these patients is poor. Few cases of CLL with CNSi have been reported until now, and ibrutinib was successfully used due to its ability to penetrate the blood-brain barrier.
ER  -

REDA, Gianluigi, Ramona CASSIN, Gabriela DOVRTĚLOVÁ, Cristina MATTEO, Juri GIANNOTTA, Maurizio D'INCALCI, Agostino CORTELEZZI and Massimo ZUCCHETTI. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. \textit{Haematologica}. Itálie: Ferrata Storti Foundation, 2019, vol.~104, No~5, p.~''E222-E223'', 2 pp. ISSN~0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2018.213157.

Detailed Information on Publication Record